You can buy or sell Epizyme and other stocks, options, ETFs, and crypto commission-free!
Epizyme, Inc. Common Stock, also called Epizyme, is a clinical-stage biopharmaceutical company, which engage in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Read More Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. It also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA.
52 Week High
52 Week Low
Seeking AlphaMar 12
Epizyme closes $172M capital raise
Epizyme (EPZM +1.4% ) has closed its concurrent offerings of common stock and convertible preferred stock, yielding gross proceeds of $172.5M....
Stock Price, News, & Analysis for Epizyme
Epizyme, Inc., a late-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases primarily in the United States. The company's lead products candidate is tazemetostat, an inhibitor of the EZH2 histone methyltransferase, which is in the Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma (NHL); Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP...
Seeking AlphaMar 7
Epizyme prices equity offerings; shares down 4% premarket
Epizyme (NASDAQ:EPZM) is down 4% premarket on light volume in reaction to the pricing of its concurrent public equity offerings. 10M shares of common stock at $11.50 per share. Underwriters over-allotment is an additional 1.5M shares. 304,348 shares of non-voting Series A Convertible Preferred Stock at $115 per share. Underwriters over-allotment is an additional 45,652 shares. Closing date for both is March 11. Net proceeds will fund global development and commercialization costs of tazemetostat outside...
Expected May 7, Pre-Market